Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial.
Name:
PIIS030228381730516X.pdf
Size:
415.8Kb
Format:
PDF
Description:
Open access full text article ...
Authors
Parker, CColeman, R
Sartor, O
Vogelzang, N
Bottomley, D
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Widmark, A
Johannessen, D
Hoskin, P
James, N
Solberg, A
Syndikus, I
Kliment, J
Wedel, S
Boehmer, S
Dall'Oglio, M
Franzén, L
Bruland, O
Petrenciuc, O
Staudacher, K
Li, R
Nilsson, S
Affiliation
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UKIssue Date
2017-07-10
Metadata
Show full item recordAbstract
In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.Citation
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial. 2017 Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2017.06.021PubMed ID
28705540Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2017.06.021
Scopus Count
Collections
Related articles
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
- Authors: Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C
- Issue date: 2014 Nov
- Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
- Authors: Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D
- Issue date: 2016 Nov
- Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
- Authors: Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N
- Issue date: 2019 May
- Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
- Authors: Nilsson S
- Issue date: 2014
- Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
- Authors: Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C
- Issue date: 2016 Jul